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Background: Estimates of the prevalence of irritable bowel syndrome (IBS) vary widely, and a large proportion of
patients report having consulted their general practitioner (GP). In patients with new onset gastrointestinal
symptoms in primary care it might be possible to predict those at risk of persistent symptoms. However, one of the
difficulties is identifying patients within primary care. GPs use a variety of Read Codes to describe patients
presenting with IBS. Furthermore, in a qualitative study, exploring GPs’ attitudes and approaches to defining
patients with IBS, GPs appeared reluctant to add the IBS Read Code to the patient record until more serious
conditions were ruled out. Consequently, symptom codes such as ‘abdominal pain’, ‘diarrhoea’ or ‘constipation’ are
used. The aim of the current study was to investigate the prevalence of recorded consultations for IBS and to
explore the symptom profile of patients with IBS using data from the Salford Integrated Record (SIR).
Methods: This was a database study using the SIR, a local patient sharing record system integrating primary,
community and secondary care information. Records were obtained for a cohort of patients with gastrointestinal
disorders from January 2002 to December 2011. Prevalence rates, symptom recording, medication prescribing and
referral patterns were compared for three patient groups (IBS, abdominal pain (AP) and Inflammatory Bowel Disease
(IBD)).
Results: The prevalence of IBS (age standardised rate: 616 per year per 100,000 population) was much lower than
expected compared with that reported in the literature. The majority of patients (69%) had no gastrointestinal
symptoms recorded in the year prior to their IBS. However a proportion of these (22%) were likely to have been
prescribed NICE guideline recommended medications for IBS in that year. The findings for AP and IBD were similar.
Conclusions: Using Read Codes to identify patients with IBS may lead to a large underestimate of the community
prevalence. The IBS diagnostic Read Code was rarely applied in practice. There are similarities with many other
medically unexplained symptoms which are typically difficult to diagnose in clinical practice.
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Irritable Bowel Syndrome (IBS) is a common gastrointes-
tinal condition defined as ‘a functional bowel disorder in
which abdominal pain or discomfort is associated with
defecation or a change in bowel habit, and with fea-
tures of disordered defecation’ [1]. Prevalence esti-
mates for IBS appear to vary widely according to the
criteria used, population studied, the mode of study
delivery and type of prevalence estimate. Typically es-
timates range between 2% and 22% in western countries
[2]. In the UK, a community survey estimated the preva-
lence of IBS to be 10.5% with over half of patients having
consulted their general practitioner (GP) within the past
six months [3].
Medical management of IBS symptoms is empiric
usually involving anti-spasmodics, anti-diarrhoeals or
laxatives as appropriate to symptoms; and antidepres-
sants, particularly low-dose tricyclic antidepressants [4].
Unfortunately, for some patients medical management is
unsatisfactory. For patients with symptoms resistant to
conventional medical therapy, current guidelines recom-
mend referral for psychological intervention to cognitive
behavioural therapy (CBT) or hypnotherapy [4].
Halder et al. [5] showed that in patients with new on-
set gastrointestinal symptoms in primary care it might
be possible to predict those at risk of persistent symp-
toms. Thus it might be possible to identify those patients
at risk of doing worse and fast-track them to these therap-
ies. This should lead to less distress and lower healthcare
utilisation for these patients in the long run. We aimed
to test this finding prospectively as a part of a NIHR
(National Institute for Health Research) programme of
work (RP-PG-0407-10136). However, one of the difficul-
ties encountered in previous work on IBS within primary
care is the identification of patients.
GPs use a variety of Read Codes to describe patients
presenting with IBS. Furthermore, in a qualitative study
to explore GPs attitudes and approaches to defining,
diagnosing and managing patients with IBS in primary
care we found that, despite recent guidelines from the
National Institute for Health and Clinical Excellence
(NICE) [4], IBS is still regarded as a diagnosis of exclu-
sion, and GPs are reluctant to add the IBS Read Code to
the patient record until more serious conditions are
ruled out [6]. As a consequence, symptom codes such as
‘abdominal pain’, ‘diarrhoea’ or ‘constipation’ are Read
coded in the patient record. To our knowledge the range
of Read Codes used by GPs to define IBS has not previ-
ously been investigated. We therefore used a database
study to investigate the use of Read Codes in patients
with IBS. In addition, two recent systematic reviews have
found that the quality of coding of morbidities within
primary care varied, and this has been attributed to the
distinctiveness of the diagnosis [7,8]. We therefore alsowished to explore the differences in coding between a
‘functional’ and an ‘organic’ disorder.
Aim
The aim of the current study was to investigate the
prevalence of recorded consultations for IBS and to ex-
plore the symptom profile of patients with IBS using
data from the Salford Integrated Record (SIR). Patients
with IBS were our primary group of interest, but we
were also interested in how GPs coded patients with
other gastrointestinal conditions, to determine whether
there were any differences in coding practices across
conditions. Patients with abdominal pain (AP) were
chosen because it is the main feature of IBS, and must
be present with two other symptoms to fulfil a diagnosis
of IBS [4]. In addition, we selected patients with IBD be-
cause IBD is an organic disorder in which patients
present with similar symptoms to IBS and we wished to
explore differences in coding practices between a ‘func-
tional’ and an ‘organic’ disorder.
Methods
Setting
The setting for this study was Salford Primary Care
Organisation, North West of England with an estimated
population of 228,992 in 2010 [9].
Population
All patients registered with the 52 General Practices in
Salford Primary Care Organisation.
Data collection and coding
The SIR is a local patient sharing record system which
integrates primary care, community care and secondary
care information into one continuous electronic health
record per patient. It is especially important for patients
with long-term conditions, who may see many health
professionals, saving the patient from having to repeat
the same information multiple times. An anonymised
dataset is made available for research through the aus-
pices of North West e-Health.
Electronic clinical records from the SIR were obtained
for a cohort of patients based on symptom and diagnostic
codes for gastrointestinal disorders for the period January
2002 to December 2011. Information was supplied in two
separate files: the first contained anonymised patient iden-
tifiers, sex and year of birth; the second contained journal
entry identifier, anonymised patient identifier, date of jour-
nal entry, Read Code description and Read Code. The files
were matched on patient identifier, and checked for dupli-
cates and anomalies. Duplicate records and patients under
the age of 17 were removed. Read Codes were then coded
into a new variable to distinguish between symptom and/
or diagnostic codes, medication codes and referral codes.
Table 1 Demographic information for patients with IBS,
AP and IBD, Salford 2002-2011
IBS AP IBD
n % n % n %
Female 6137 72.7 26071 61.4 755 50.0
Age 18-39 4373 51.8 19662 46.3 629 41.7
40-59 2703 32.0 13379 31.5 487 32.3
60+ 1368 16.2 9449 22.2 394 26.1
Figure 1 Age standardised rates, Salford 2002–2011.
Harkness et al. BMC Family Practice 2013, 14:183 Page 3 of 10
http://www.biomedcentral.com/1471-2296/14/183Analysis
For the study we carried out analysis on three groups.
These were patients with:
a) IBS (Read Codes 14CF. and J521. including any
subheadings)
b) abdominal pain (Read Codes 196.., 197.. and R090.
including any subheadings)
c) Inflammatory Bowel Disease (IBD) (Read Codes J4…
(without subheadings), J40.. and J41.. including any
subheadings)
For each group of patients we identified an index episode
of IBS, abdominal pain or IBD. For each index episode, an
index date was created based on the date for that particular
journal entry. For each condition we then looked one year
pre and post the index date to determine:
i) Symptoms/diagnoses recorded pre and post IBS,
abdominal pain and IBD
ii) Medications prescribed pre and post IBS, abdominal
pain and IBD
iii)Referrals to gastrointestinal (GI) specialists pre and
post IBS, abdominal pain and IBD
The index episode was taken as the first occurrence of
IBS, abdominal pain or IBD. The date of this episode
was then used to calculate the number of days between
the index episode and all corresponding journal entries
for the same patient. Where the journal entry date was
the same as the index date symptoms/diagnoses were in-
cluded in the previous year and medications and refer-
rals were included in the year after the index episode.
Pre- episode data was based on those with an index epi-
sode between 2003 and 2011 (so that only those with a
complete year of data available before the index year
were included), likewise post-episode data was based on
those with an index episode between 2002 and 2010.
We also calculated prevalence estimates based on
Salford population data. Population data was obtained
from the Office of National Statistics (ONS) website for
Salford Primary Care Organisation [9]. Rates were stan-
dardised to the Greater Manchester population for 2006.
This includes the population of the ten primary care orga-
nisations within the Greater Manchester area, which is
roughly 2.5 million.
Results
There were 8,444 patients in Salford with an IBS Read
Code recorded in the years 2002 to 2011. AP and IBD were
Read Coded for 42,490 and 1,510 patients respectively.
IBS and AP were much more common in females,
whereas a similar proportion of males and females had
IBD (Table 1). The highest proportion of those with IBS,AP or IBD was in those aged 18–39 and declined with
age. More patients with IBD were aged 60 or over (26%)
compared with those aged 60 or over with IBS (16%)
and AP (22%).
Prevalence estimates
The age standardised rates for IBS, AP and IBD per year
per 100,000 population were 616, 3,606 and 139 respect-
ively. Figure 1 shows the age standardised rates per
100,000 population for IBS, AP and IBD by gender in
Salford for the years 2002–2011. Rates have been stan-
dardised to the Greater Manchester population. The
rates for IBD have remained stable across the ten year
period for both males and females. IBS shows a similar
pattern in males and females with a slight increase in
prevalence rates up to 2006 before levelling out over the
second half of the ten year period. The rates of AP on
the other hand increased considerably in both males and
females from 2002 to about 2009, after which they have
levelled out for both males and females.
Symptoms pre and post IBS, AP or IBD
Table 2 shows the number of symptoms/diagnoses one
year prior to and one year after the index episode of IBS,
AP and IBD. The most commonly reported symptoms
in the year prior to IBS were AP (19.5%), diarrhoea
(6.1%) and bloating (3.8%). However, for most patients
Table 2 Number (%) of symptoms pre and post IBS, AP and IBD, Salford 2002-2011
Pre IBS
(n = 7728)
Post IBS
(n = 7665)
Pre AP
(n = 39974)
Post AP
(n = 37851)
Pre IBD
(n = 1336)
Post IBD
(n = 1382)
Symptoms/diagnoses* n % n % n % n % n % n %
Abdominal pain 1509 19.5 1028 13.4 - - 8683 22.9 212 15.9 144 10.4
Bloating 291 3.8 137 1.8 411 1.0 374 1.0 8 0.6 7 0.5
Constipation symptom 166 2.1 138 1.8 639 1.6 700 1.8 16 1.2 14 1.0
Change in bowel habit 130 1.7 45 0.6 175 0.4 174 0.5 46 3.4 5 0.4
Diarrhoea symptoms 475 6.1 256 3.3 1046 2.6 972 2.6 158 11.8 74 5.4
Nausea 104 1.3 100 1.3 483 1.2 513 1.4 6 0.4 12 0.9
Vomiting 72 0.9 67 0.9 583 1.5 583 1.5 11 0.8 19 1.4
Diarrhoea & vomiting 47 0.6 43 0.6 202 0.5 192 0.5 12 0.9 6 0.4
Tenesmus 2 0.0 2 0.0 6 0.0 12 0.0 2 0.1 0 0.0
Faeces/motion symptoms 31 0.4 34 0.4 72 0.2 80 0.2 8 0.6 4 0.3
None of the above symptoms 5367 69.4 6062 79.1 36994 92.5 27010 71.4 930 69.6 1143 82.7
1 of the above symptoms 1950 25.2 1380 18.0 2699 6.8 9555 25.2 339 25.4 200 14.5
2 or more of the above symptoms 411 5.3 223 2.9 281 0.7 1286 3.4 67 5.0 39 2.8
Functional constipation 151 2.0 121 1.6 511 1.3 573 1.5 20 1.5 21 1.5
Functional diarrhoea 31 0.4 31 0.4 75 0.2 118 0.3 22 1.6 15 1.1
GI infection 84 1.1 63 0.8 295 0.7 295 0.8 18 1.3 8 0.6
IBS - - 1090 14.2 747 1.9 1061 2.8 42 3.1 25 1.8
IBD 33 0.4 40 0.5 128 0.3 204 0.5 - - 391 28.3
*Symptoms on the same day were coded as pre.
Harkness et al. BMC Family Practice 2013, 14:183 Page 4 of 10
http://www.biomedcentral.com/1471-2296/14/183(69.4%) no GI symptoms were recorded in the year prior
to their IBS. Likewise in the year after the index episode of
IBS most patients did not have any GI symptoms recorded
(79.1%), AP was the most commonly recorded symptom
(13.4%) and 14% of patients had a further episode of IBS
recorded in the year after their index episode. IBD showed
a similar pattern to IBS with the majority of patients
(69.6%) not having any symptoms recorded in the year
prior to their IBD diagnosis. The most commonly re-
ported symptoms were AP (15.9%) and diarrhoea (11.8%).
In the year after the index episode of IBD, AP and diar-
rhoea were still the most commonly reported symptoms
but the proportions tended to be lower (10.4% and 5.4%
respectively). Almost a third of patients had a further epi-
sode of IBD recorded in the year after their index episode.
For patients with AP most patients (92.5%) had no
symptoms recorded in the year prior to their index epi-
sode of AP. In the year after their index episode, 23% of
patients had a further AP episode, and 2.8% of patients
had an IBS diagnosis.
The proportion of patients who reported two or more
symptoms in the previous year or the year after IBS, AP
or IBD was coded in 5% or less in most instances.
Medications pre and post IBS, AP or IBD
Table 3 shows the number of NICE guideline recom-
mended medications for IBS prescribed in the year priorto and after the index episode of IBS, AP and IBD. NICE
guideline recommended medications for IBS were pre-
scribed for 31% and 54% of patients in the year prior to
and after their index episode of IBS respectively. The in-
creased use of these medications was most marked for
antispasmodics which increased from 17% in the year
prior to IBS to 44% in the year after. IBS NICE guideline
recommended medications were also commonly pre-
scribed in patients with AP and IBD, with about a third
of patients being prescribed medications in the year after
the index episode of AP or IBD. Prescribing of antispas-
modics increased markedly from 5% to 19% in those with
AP pre- and post- the index episode. Approximately 10%
of patients with IBS, AP or IBD were prescribed selective
serotonin reuptake inhibitors (SSRIs), and about 5% tri-
cyclic antidepressants.
Tables 4 and 5 show the number of NICE guideline
recommended medications prescribed in the year prior
to and year after the index episodes of IBS, AP and IBD
for those with and without symptoms respectively.
Where GI symptoms were recorded in the year prior to
or the year after the index episode, the proportion of
patients prescribed NICE guideline recommended medi-
cations was higher than in those without symptoms.
However, a number of patients still received NICE
guideline recommended medications in the year prior to
their index episode of IBS (22%), AP (18%) or IBD (20%)
Table 3 Number (%) of medications pre and post IBS, AP and IBD, Salford 2002-2011
Pre IBS
(n = 7728)
Post IBS
(n = 7665)
Pre AP
(n = 39974)
Post AP
(n = 37851)
Pre IBD
(n = 1336)
Post IBD
(n = 1382)
Medications† n % n % n % n % n % n %
NICE medications 2395 31.0 4099 53.5 8560 21.4 13871 36.6 389 29.1 442 32.0
Bulking laxatives 288 3.7 629 8.2 754 1.9 1561 4.1 40 3.0 50 3.6
Stimulant laxatives 204 2.6 247 3.2 1106 2.8 1688 4.5 36 2.7 59 4.3
Faecal softeners 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Osmotic laxatives 216 2.8 289 3.8 845 2.1 1550 4.1 27 2.0 50 3.6
Antimotility drugs 246 3.2 429 5.6 727 1.8 979 2.6 132 9.9 169 12.2
Antispasmodic drugs 1328 17.2 3397 44.3 1890 4.7 7035 18.6 157 11.8 149 10.8
Tricyclic antidepressants 397 5.1 553 7.2 1924 4.8 2221 5.9 66 4.9 78 5.6
SSRI 808 10.5 957 12.5 3530 8.8 3955 10.4 101 7.6 129 9.3
Other antidepressants 124 1.6 147 1.9 554 1.4 660 1.7 12 0.9 15 1.1
†Medications on the same day were coded as post.
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prior to their index episode. In those with IBS approxi-
mately 50% of those with no symptoms recorded in the
year after their index episode were prescribed NICE
guideline recommended medications, compared with
about 30% in those with AP or IBD. In those where
symptoms had been recorded in the year prior to or
after the index episode the proportion prescribed NICE
guideline recommended medications was much higher
compared to those where no symptoms had been
recorded.
Referrals pre and post IBS, AP or IBD
About 4% of patients had a gastrointestinal secondary
care referral either in the year prior to or the year after
their index episode of IBS (Table 6). This was in contrast
to patients with IBD where 9% of patients had a GITable 4 Number (%) of medications pre and post IBS, AP, IBD
Pre IBS
(n = 5367)
Post IBS
(n = 6062)
P
(n =
Medications† n % n % n
NICE medications 1176 21.9 2974 49.1 6720
Bulking laxatives 119 2.2 437 7.2 569
Stimulant laxatives 77 1.4 129 2.1 795
Faecal softeners 0 0.0 0 0.0 0
Osmotic laxatives‡ 93 1.7 152 2.5 571
Antimotility drugs 109 2.0 284 4.7 423
Antispasmodic drugs 533 9.9 2430 40.1 1414
Tricyclic antidepressants 228 4.2 372 6.1 1647
SSRI 471 8.8 680 11.2 3061
Other antidepressants 55 1.0 84 1.4 472
†Medications on the same day were coded as post.
‡Excludes lactulose which is not recommended in NICE guidelines.referral in the year prior to their index episode and 22%
had a GI referral in the year after their index episode.
Few patients (0.9%) with AP had a GI referral in the year
prior to their index episode. The number of referrals for
mental health or lifestyle was low (0.0% to 0.7%) for all
three conditions.
Discussion
Summary
This database study demonstrated that the prevalence of
IBS in patients who consult, and are recorded by, their
GP was low compared with the reported prevalence
rates in the literature [2]. Most patients who had an IBS
Read Code recorded did not have any gastrointestinal
symptoms recorded prior to or after their index date.
Likewise the majority of patients with AP or IBD did not
have any symptoms recorded prior to or after their indexin those with no symptoms, Salford 2002-2011
re AP
36670)
Post AP
(n = 27010)
Pre IBD
(n = 930)
Post IBD
(n = 1143)
% n % n % n %
18.3 8018 29.7 191 19.9 300 26.2
1.6 840 3.1 21 2.2 32 2.8
2.2 896 3.3 19 2.0 33 2.9
0.0 0 0.0 0 0.0 0 0.0
1.6 745 2.8 13 1.4 25 2.2
1.2 450 1.7 66 6.9 119 10.4
3.9 3870 14.3 55 5.7 85 7.4
4.5 1364 5.0 46 4.8 52 4.5
8.3 2488 9.2 59 6.1 92 8.0
1.3 383 1.4 8 0.8 10 0.9
Table 5 Number (%) of medications pre and post IBS, AP, IBD in those with symptoms, Salford 2002-2011
Pre IBS
(n = 2361)
Post IBS
(n = 1603)
Pre AP
(n = 3304)
Post AP
(n = 10841)
Pre IBD
(n = 406)
Post IBD
(n = 239)
Medications† n % n % n % n % n % n %
NICE medications 1181 50.0 1103 68.8 1466 44.4 5314 49.0 189 46.6 135 56.5
Bulking laxatives 169 7.2 192 12.0 185 5.6 721 6.7 19 4.7 18 7.5
Stimulant laxatives 127 5.4 118 7.4 311 9.4 792 7.3 17 4.2 26 10.9
Faecal softeners 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Osmotic laxatives‡ 123 5.2 137 8.5 274 8.3 805 7.4 14 3.4 25 10.5
Antimotility drugs 137 5.8 145 9.0 304 9.2 529 4.9 66 16.3 50 20.9
Antispasmodic drugs 795 33.7 967 60.3 476 14.4 3165 29.2 102 25.1 64 26.8
Tricyclic antidepressants 169 7.2 181 11.3 277 8.4 857 7.9 20 4.9 26 10.9
SSRI 337 14.3 277 17.3 469 14.2 1467 13.5 42 10.3 37 15.5
Other antidepressants 69 2.9 63 3.9 82 2.5 277 2.6 4 1.0 5 2.1
†Medications on the same day were coded as post.
‡Excludes lactulose which is not recommended in NICE guidelines.
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scribed medications for patients with IBS. A significant
proportion of patients were prescribed IBS NICE guide-
line recommended medications in the year prior to their
IBS being Read Coded. A small proportion of patients
with IBS were referred to GI specialists.
Strengths and limitations
A major advantage of the SIR is the complete linkage be-
tween primary care, community care and secondary care
datasets, providing a continuous electronic record for
each patient in contact with health services in Salford.
However, there were certain limitations in using these
data for identifying patients with IBS in our study.
We were unable to validate the dataset. Ideally we
would have created a cohort of IBS patients from SIR
and validated the diagnosis by asking their GPs [10]
but this was not possible since the SIR for research is
anonymised at both patient and GP level. In addition,
a number of computerised systems are available for
capturing clinical consultation data in primary care
and several different versions of the various operating
systems are in use so there may be slight variations
at computer operating system level that would have
impeded our research.
There are also idiosyncrasies in the Read Code tax-
onomy, in particular the fact that codes for a lack ofTable 6 Number (%) of referrals pre and post IBS, AP and IBD
Pre IBS
(n = 7728)
Post IBS
(n = 7665)
Pre A
(n = 399
Referrals# n % n % n
Gastrointestinal 295 3.8 288 3.8 358
Mental health 3 0.0 3 0.0 19
Lifestyle 24 0.3 24 0.3 79
#Referrals on the same day were coded as post.existence of a symptom can occur as leaf nodes describ-
ing that symptom. For example, the Read Code for “no
abdominal pain” (1961.) is included under one of the
Read Codes for abdominal pain (196..). However, it
seems that GPs might be reluctant to document patients
using such negated child node Read Codes as less than
0.1% were found in the data set we used.
Read Codes used to code a consultation are at the dis-
cretion of the individual clinician, which means that
there can be considerable variation in their use to de-
scribe the same set of symptoms in practice (particularly
for conditions not incentivised in the Quality Outcomes
Framework (QOF)). However, research requires a disci-
plined approach to data entry and retrieval [11], so that
inconsistency in coding potentially presents an import-
ant source of information bias.
Recorded prevalence of IBS consultations
This study demonstrates that the recorded prevalence of
IBS in patients who consult their GP is low. In the
current study, we not only looked at the prevalence of IBS
Read Codes in primary care, but the prevalence of AP, the
main presenting feature for IBS. Even rates of AP were
less than those reported for IBS in the literature. Reassur-
ingly we found similar results using data extracted from
Manchester Primary Care Organisation (data not shown)
suggesting that the current findings are not an artefact of, Salford 2002–2011
P
74)
Post AP
(n = 37851)
Pre IBD
(n = 1336)
Post IBD
(n = 1382)
% n % n % n %
0.9 1230 3.2 123 9.2 303 21.9
0.0 21 0.1 0 0.0 0 0.0
0.2 99 0.3 6 0.4 9 0.7
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A, Whorwell P, Lovell K, et al.: Evaluating and Implement-
ing Better Patient-Orientated Management of Chronic
Gastrointestinal Disorders in Primary Care. Programme
Grants Appl Res 2014, in review).
There are several possible explanations for the lower
than expected prevalence of patients consulting with,
and recorded as having, IBS.
Firstly, many of the studies estimating the prevalence
of IBS have been self-report questionnaire surveys, and
may have overestimated the proportion of patients who
have been formally diagnosed with IBS, or who seek
healthcare for their symptoms. Nevertheless the consult-
ation prevalence for IBS was much lower than expected
and the literature suggests that GPs see IBS as a signifi-
cant problem [12]. Our findings reflect those in rheuma-
tology where large discrepancies have been found in the
consultation prevalence of knee pain when comparing
primary care records with patient recall [13]. These dis-
crepancies are as a result of ‘telescoping’ by patients and
under recording by GPs, in particular, if patients present
with multiple problems or have previously consulted for
the same condition [13]. Like knee pain, IBS does not
have a definite diagnosis and symptoms fluctuate over
time, thus primary care records may only reflect the
consultation prevalence of IBS when it forms a major
part of the consultation. Moreover, Jordan at el. [13]
found that consultation rates increased when the text of
the consultation was used in addition to Read Codes
alone. Others have also discussed the benefit of narra-
tives during the consultation rather than reducing the
clinical encounter to a limited number of codes [14].
Secondly, IBS or GI symptoms, are not included in the
Quality Outcomes Framework (QoF), a scheme that
incentivises GP practices and rewards them according to
how well they care for patients. Consequently, recording
IBS is not likely to be a priority for GPs and therefore
may be patchy.
Thirdly, GPs appear to be reluctant to code patients
for IBS or lower GI symptoms. The IBS diagnosis in pri-
mary care appears to be different to, and less exclusive
than existing diagnostic criteria [15]. The usefulness of
diagnostic criteria is frequently debated in the literature
[16-20] and they tend to be of little relevance within pri-
mary care, as few GPs are familiar with the criteria and
they do not use them to make a diagnosis [17,21,22]. In
our qualitative study to investigate how GPs defined, diag-
nosed and managed patients with IBS, we found that whilst
most GPs were aware of the NICE guideline [4] for IBS,
few used it to help them make a diagnosis of IBS and add a
Read Code to the patient record [6]. Instead they described
using an iterative process to exclude sinister symptoms
and as a result perhaps not applying a Read Code to the
patient record when they first consult.Fourthly, recorded prevalence depends on the health-
care seeking behaviour of patients. Patients may not
consult their GP for IBS for a number of reasons. They
may only consult when their symptoms are severe and,
consequently, they perhaps feel less able to cope. Indeed,
data from our risk assessment study, where patients
were recruited either via the consultation or through the
use of Read Code searches (and had to have consulted
for IBS symptoms in the last three months), suggest that
the majority of patients had moderate or severe symp-
toms (Thompson DG, O’Brien S, Kennedy A, Rogers A,
Whorwell P, Lovell K, et al.: Evaluating and Implement-
ing Better Patient-Orientated Management of Chronic
Gastrointestinal Disorders in Primary Care. Programme
Grants Appl Res 2014, in review). Evidence suggests that
symptom severity may have an influence on health care
seeking but that it does explain the majority of the con-
sultation behaviour [23]. Psychological and psychosocial
factors have also been implicated in health care seeking
behaviours for patients with IBS [24,25]. The present
study suggests that a proportion of patients with IBS, AP
and IBD were prescribed anti-depressants in the year
before and the year after their index episode. How-
ever, we cannot infer whether these medications were
prescribed for their gastrointestinal symptoms, for re-
lated anxiety and/or depression, or for unrelated anx-
iety and/or depression.
Furthermore, patients may not consult their GP for their
IBS because their symptoms are under control through
the use of medication or self-management. A relatively
large proportion of patients in the current study had no
GI symptoms in the year prior to their index episode of
IBS but had been prescribed IBS medications, as recom-
mended in the NICE guideline [4]. However, we are un-
able to say whether these patients had ever been recorded
as having IBS prior to the year before their index episode,
and whether they had received a repeat prescription from
their GP for their symptoms.
Finally, patients may feel there is little that primary
care can offer, and therefore learn to live with their
symptoms. Stenner et. al. [26] reported that patients felt
that doctors were unsympathetic and ignorant about
IBS, and often considered IBS ‘all being in the mind’ of
the patient. Others felt GPs were responsible for the
worsening of their condition as a result of their ignor-
ance of IBS or ‘through the iatrogenic effects of treat-
ment’ [26]. Farndale et al. [27] found that IBS patients
report alienation from health services for similar rea-
sons. In addition, moderate to high levels of perceived
stigma are significantly greater in IBS patients (27%)
compared to IBD patients (8%), with the largest differ-
ence being for health care providers [28]. It is, therefore,
perhaps unsurprising that a proportion of those suffering
from the symptoms of IBS do not consult their GP and
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Although alternative therapies are not recommended
within the NICE guidance [4] our qualitative study
showed that GPs did not discourage their use [6].Table 7 Symptoms/diagnoses were defined as any of the
following
Symptom/diagnoses Read
codes
Rubric
Irritable bowel syndrome 14CF. History of IBS
J521. IBSIBS and GI symptoms
Our study found that the majority of patients who were
coded as having IBS did not have GI symptoms recorded
in the year prior to or the year after their index episode.
NICE recommends assessment for IBS in patients having
any of the following for at least 6 months: abdominal
pain or discomfort, bloating or change in bowel habit.
Therefore one might expect evidence of this in the re-
cording of symptom codes in the year prior to or after
the index episode of IBS. However, this was not the case,
despite using symptom codes in order to be as compre-
hensive as possible and by including other related symp-
toms, such as nausea and vomiting, tenesmus and faeces/
motions. Interestingly though, IBS medications as recom-
mended by NICE were often prescribed in those without
recorded symptoms in the year prior to their IBS. GPs in
the qualitative study also described making a diagnosis
based on the patient response to a trial of medication [6].
This suggests that the use of medication codes may be an
alternative approach to identifying patients via symptom
or diagnostic Read Codes. GPs must enter a medication
on their clinical system in order for a prescription to be is-
sued. However this approach may include patients with
other diagnoses as some IBS medications (e.g. laxatives)
may also be prescribed for other conditions.
Findings from our qualitative study suggest GPs did
not describe difficulties in managing patients with IBS
[6]. This is also evident in the current study where a
relatively small proportion of patients with IBS had a re-
ferral to a GI specialist, compared to those patients with
a diagnosis of IBD.Abdominal pain 196.. Type of gastrointestinal tract pain
197.. Site of gastrointestinal tract pain
R090. [D] Abdominal pain
Bloating 19A.. Abdominal distension symptom
19B.. Flatulence/wind
R0734 [D] Bloating
Constipation symptom 19C.. Constipation
Functional constipation J520. Constipation - functional
Change in bowel habit 19EA. Change in bowel habit
R078. [D] Change in bowel habit
Diarrhoea 19F.. Diarrhoea symptoms
19G.. Diarrhoea and vomiting
Functional diarrhoea J525. Functional diarrhoea
J43z. Chronic diarrhoea
J4z.. Presumed noninfectious diarrhoeaSimilarities with other medically unexplained symptoms
Similarities can be seen with other medically unex-
plained symptoms such as fibromyalgia and chronic fa-
tigue syndrome. For example, Rohrbeck et al. [29] found
the recorded annual prevalence of fibromyalgia in pri-
mary care to be 8 per 10 000 which is much lower
than the estimated general population prevalence of
2%. This implies that the label of fibromyalgia is rarely
used within general practice [29]. They also found that
fibromyalgia patients are similar to those with overlapping
functional syndromes or medically unexplained symptoms
[29]. Similarly, in his review of medically unexplained
symptoms in primary care, Burton [30] reported that
many patients with IBS met the criteria for fibromyalgia
and chronic pelvic pain. This overlap with other medically
unexplained symptoms, which often appear to sharesimilar psychosocial characteristics, creates further diag-
nostic complexities.
Conclusions
Our findings suggest that the use of symptom /and or
diagnostic Read Codes to identify patients with IBS in
primary care is questionable and likely to lead to large
underestimates of both the community incidence and
prevalence. The discrepancies between the self-reported
prevalence rates in the literature and those for consulta-
tions within the primary care record, suggest that there
may be conflicting priorities between patients and health
care professionals, and that database studies, are useful
in only identifying the ‘tip of the iceberg’.
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Appendix
Tables 7, 8 and 9.
Table 7 Symptoms/diagnoses were defined as any of the
following (Continued)
Nausea 198.. Nausea
Vomiting 199.. Vomiting
Diarrhoea and vomiting 19G.. Diarrhoea and vomiting
Tenesmus 19D.. Tenesmus symptom
Faeces/motions
symptoms
19E.. Faeces/motions -symptoms
GI infection A0… Intestinal infectious diseases
Inflammatory bowel
disease
J40.. Crohn’s disease
J41.. Ulcerative colitis or proctitis
Table 8 Medications were defined on the basis of the
NICE guidelines [4] and were coded as follows
NICE medications Read
codes
Rubric
Bulk-forming laxatives ab2.. Isphagula husk
ab3.. Methylcellulose
ab4.. Sterculia
Stimulant laxatives ac5.. Docusate sodium
ac7.. Senna
ac8.. Sodium picosulphate
af1.. Rectal laxatives (Glycerol, biascodyl)
ac1.. Biascodyl
Faecal softeners ad1.. Liquid paraffin
Osmotic laxatives ae4.. Polyethylene glycols
a12.. Magnesium salts – antacid
ae2.. Magnesium hydroxide
ae3.. Magnesium sulphate
ae7.. Sodium phosphate
Antimotility agents a81.. Codeine phosphate
a82.. Diphenoxylate hydrochloride
a83.. Loperamide: single drug
a85.. Loperamide: compound preparation
a842. Kaolin and morphine mixture
Antispasmodics a41.. Atrophine sulphate
a45.. Dicycloverine hydrochloride
a47.. Hyoscine butylbromide
a4c.. Propantheline bromide
a4d.. Alverine citrate
a4e.. Mebeverine hydrochloride
a4f.. Peppermint oil
Antidepressants
Tricyclics and related
antidepressants
d71.. Amitripyline
d91.. Triptafen
Table 8 Medications were defined on the basis of the
NICE guidelines [4] and were coded as follows (Continued)
d73.. Clomipramine hydrochloride
d75.. Dosulephin hydrochloride
d76.. Doxepin
d77.. Imipramine hydrochloride
d79.. Lofepramine
d7c.. Nortriptyline
d7f.. Trimipramine
d7b.. Mianserin hydrochloride
d7e.. Trazodone hydrochloride
da9.. CitalopramSelective serotonin
re-uptake inhibitors (SSRIs)
daC.. Escitalopram
Monoamine oxidase
inhibitors (MAOIs)
da4.. Fluoxetine hydrochloride
Reversible MAOIs da3.. Fluvoxamine maleate
da6.. Paroxetine hydrochloride
da5.. Sertraline hydrochloride
Other antidepressants d81.. Phenelzine
d83.. Isocarboxazid
d84.. Tranylcypromine
d85.. Moclobemide
gde.. Duloxetine
da1.. Flupentixol
daB.. Mirtazapine
daA.. Reboxetine
da2.. Tryptophan
Table 9 Referrals to specialists or for further for
investigation of gastrointestinal symptoms were defined
as any of the following
Referral Read
codes
Rubric
Specialist
referral
8h48. Gastroenterological referral
8h5J. Referral to colorectal surgeon
8H5K. Referral to upper gastrointestinal surgeon
8HL8. Gastroenterology DV done
8HM8. Listed for gasterenterol admis
8Hn4. Fast track referral for suspected colorectal cancer
8Hn9. Fast track referral for suspected upper GI cancer
8HS.. Refer for gastroscopy
8HS0. Refer for sigmoidoscopy
8HU1. Referral for colonoscopy
8HU2. Referral for sigmoidoscopy
8HVc. Private referral to colorectal surgeon
8HVN. Private referral to gastroenterologist
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